ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).

被引：0
|
作者：
Ma, Fei
Qiu, Fuming
Tong, Zhongsheng
Shi, Yehui
Yu, Guohua
Wu, Xinhong
Wang, Hong
Wang, Jiani
Yang, Hua
Liu, Anwen
Zhang, Yan
Zheng, Hongmei
Lan, Qiongyu
Zhang, Yongqiang
Cheng, Ying
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[5] Weifang Med Univ, Weifang Peoples Hosp, Weifang, Peoples R China
[6] Weifang Med Univ, Affiliated Hosp 1, Weifang, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China
[8] Hubei Prov Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[9] Wuhan Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[10] Nanchang Third Hosp, Nanchang, Jiangxi, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[12] Affiliated Hosp Hebei Univ, Baoding, Hebei, Peoples R China
[13] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[14] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[15] Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Jiangxi, Peoples R China
[16] Beijing Hosp, Beijing, Peoples R China
[17] Jilin Canc Hosp, Changchun, Peoples R China
[18] Shanghai Escugen Biotechnol Co Ltd, Shanghai, Peoples R China
[19] Shanghai Escugen Biotechnol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13132
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Development of Triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations
    Chou, Chih-Chien
    Kardos, Jordan
    Yang, Becky
    Orf, Jessica
    Dave, Rutwij
    Lai, Yurong
    Lee, Chingwei V.
    Papalia, Giuseppe A.
    Boyd, Kelli
    Diehl, Lauri
    Scholler, Nathalie
    CANCER RESEARCH, 2023, 83 (05)
  • [32] Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors
    Mertens, Richard B.
    Makhoul, Elias P.
    Li, Xiaomo
    Dadmanesh, Farnaz
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 68
  • [33] Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
    Zeybek, Burak
    Manzano, Aranzazu
    Bianchi, Anna
    Bonazzoli, Elena
    Bellone, Stefania
    Buza, Natalia
    Hui, Pei
    Lopez, Salvatore
    Perrone, Emanuele
    Manara, Paola
    Zammataro, Luca
    Altwerger, Gary
    Han, Chanhee
    Tymon-Rosario, Joan
    Menderes, Gulden
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [34] Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
    Burak Zeybek
    Aranzazu Manzano
    Anna Bianchi
    Elena Bonazzoli
    Stefania Bellone
    Natalia Buza
    Pei Hui
    Salvatore Lopez
    Emanuele Perrone
    Paola Manara
    Luca Zammataro
    Gary Altwerger
    Chanhee Han
    Joan Tymon-Rosario
    Gulden Menderes
    Elena Ratner
    Dan-Arin Silasi
    Gloria S. Huang
    Masoud Azodi
    Peter E. Schwartz
    Alessandro Santin
    Scientific Reports, 10
  • [35] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [36] Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan
    Zeybek, B.
    Manzano, A.
    Bianchi, A.
    Bonazzoli, E.
    Bellone, S.
    Buza, N.
    Hui, P.
    Lopez, S.
    Perrone, E.
    Manara, P.
    Zammataro, L.
    Altwerger, G.
    Han, C.
    Tymon-Rosario, J. R.
    Menderes, G.
    Ratner, E. S.
    Silasi, D. A.
    Huang, G. S.
    Azodi, M.
    Schwartz, P. E.
    Santin, A. D.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 177 - 177
  • [37] Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
    Zeybek, Burak
    Manzano, Aranzazu
    Bianchi, Anna
    Bonazzoli, Elena
    Buza, Natalia
    Lopez, Salvatore
    Perrone, Emanuele
    Manara, Paula
    Bellone, Stefania
    Zammataro, Luca
    Santin, Alessandro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer
    Abelman, Rachel O.
    Spring, Laura M.
    Ryan, Phoebe K.
    Fell, Geoffrey
    Juric, Dejan
    Heist, Rebecca S.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (07)
  • [39] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [40] Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Schmid, P.
    McArthur, H. L.
    Cortes, J.
    Xu, B.
    Cardoso, F.
    Casalnuovo, M. L.
    Demirci, U.
    Freitas, R., Jr.
    Ghosh, J.
    Hegg, R.
    Iwata, H.
    Chuken, Y. A. Lopez
    Nechaeva, M.
    Robson, M. E.
    Villalobos Valencia, R.
    Lloyd, A.
    D'Cruz, C.
    Foxley, A.
    Park, Y. H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1212 - 1213
12345